A PHASE 1 STUDY OF THE EZH2 INHIBITOR TAZEMETOSTAT IN PEDIATRIC SUBJECTS WITH RELAPSED/REFRACTORY INI1-NEGATIVE OR SYNOVIAL SARCOMA

Registry ID

EZH-102

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

EPIZYME, INC.

Start date

2020-06-02

Last update

2015-12-14

Conditions

• SARCOMA

Related clinical trials

• PHASE 1B/2 STUDY EVALUATING THE EFFICACY AND SAFETY OF RISVUTATUG REZETECAN IN PARTICIPANTS WITH PREVIOUSLY TREATED UNRESECTABLE ADVANCED OR METASTATIC SARCOMAS
• A SEAMLESS PHASE 1/2 OPEN-LABEL STUDY TO EVALUATE THE SAFETY, DETERMINE THE MAXIMUM TOLERATED DOSE OF ADMINISTERED ACTIVITY, AND EVALUATE THE EFFICACY OF THE THERAPEUTIC RADIOPHARMACEUTICAL [AC-225]RTX-2358 IN THE TREATMENT OF RELAPSED OR REFRACTORY SARCOMA
• A RANDOMIZED PHASE III TRIAL OF DOXORUBICIN + PEMBROLIZUMAB VERSUS DOXORUBICIN ALONE FOR THE TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS) AND RELATED POORLY DIFFERENTIATED SARCOMAS
• A RANDOMIZED PHASE I/II STUDY OF ONIVYDE IN COMBINATION WITH TALAZOPARIB OR TEMOZOLOMIDE IN CHILDREN AND YOUNG ADULTS WITH RECURRENT SOLID MALIGNANCIES AND EWING SARCOMA
• RANDOMIZED PHASE II TRIAL EVALUATING THE ADDITION OF THE IGF-1R MONOCLONAL ANTIBODY GANITUMAB (AMG 479, NSC#750008, IND#120449) TO MULTIAGENT CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED METASTATIC EWING SARCOMA
• A MULTICENTER, RANDOMIZED, OPEN-LABEL PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ALDOXORUBICIN COMPARED TO INVESTIGATOR'S CHOICE IN SUBJECTS WITH METASTATIC, LOCALLY ADVANCED, OR UNRESECTABLE SOFT TISSUE SARCOMAS WHO EITHER RELAPSED OR WERE REFRACTORY TO PRIOR NON-ADJUVANT CHEMOTHERAPY

View on source registry